questionsmedicales.fr
Virus
Virus oncogènes
Virus tumoraux à ADN
Papillomaviridae
Papillomaviridae : Questions médicales fréquentes
Termes MeSH sélectionnés :
Uterine Cervical Neoplasms
Diagnostic
5
Papillomavirus
Dépistage du cancer
Verrues
Infections virales
Col de l'utérus
Frottis cervical
Prévention du cancer
Santé publique
Symptômes
5
Symptômes
Verrues génitales
Papillomes
Infections respiratoires
Lésions cutanées
Dermatologie
Asymptomatique
Infections virales
Prévention
5
Vaccination préventive
Santé des adolescents
Dépistage
Prévention du cancer
Partenaires sexuels
Transmission virale
Habitudes de vie
Facteurs de risque
Traitements
5
Traitement antiviral
Gestion des symptômes
Vaccins
Prévention des infections
Types de HPV
Efficacité des traitements
Complications
5
Complications
Cancer du col de l'utérus
Infections bénignes
Évolution des maladies
Traitement des complications
Surveillance médicale
Suivi médical
Prévention du cancer
Facteurs de risque
5
Facteurs de risque
Système immunitaire
Partenaires sexuels
Transmission virale
Immunodépression
Infections virales
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Papillomaviridae : Questions médicales les plus fréquentes",
"headline": "Papillomaviridae : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Papillomaviridae : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-19",
"dateModified": "2026-01-08",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Papillomaviridae"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Virus tumoraux à ADN",
"url": "https://questionsmedicales.fr/mesh/D004263",
"about": {
"@type": "MedicalCondition",
"name": "Virus tumoraux à ADN",
"code": {
"@type": "MedicalCode",
"code": "D004263",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B04.613.204"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Alphapapillomavirus",
"alternateName": "Alphapapillomavirus",
"url": "https://questionsmedicales.fr/mesh/D052685",
"about": {
"@type": "MedicalCondition",
"name": "Alphapapillomavirus",
"code": {
"@type": "MedicalCode",
"code": "D052685",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B04.613.204.655.050"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Betapapillomavirus",
"alternateName": "Betapapillomavirus",
"url": "https://questionsmedicales.fr/mesh/D052686",
"about": {
"@type": "MedicalCondition",
"name": "Betapapillomavirus",
"code": {
"@type": "MedicalCode",
"code": "D052686",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B04.613.204.655.100"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Deltapapillomavirus",
"alternateName": "Deltapapillomavirus",
"url": "https://questionsmedicales.fr/mesh/D052687",
"about": {
"@type": "MedicalCondition",
"name": "Deltapapillomavirus",
"code": {
"@type": "MedicalCode",
"code": "D052687",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B04.613.204.655.200"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Papillomavirus bovin de type 1",
"alternateName": "Bovine papillomavirus 1",
"url": "https://questionsmedicales.fr/mesh/D052688",
"about": {
"@type": "MedicalCondition",
"name": "Papillomavirus bovin de type 1",
"code": {
"@type": "MedicalCode",
"code": "D052688",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B04.613.204.655.200.100"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Gammapapillomavirus",
"alternateName": "Gammapapillomavirus",
"url": "https://questionsmedicales.fr/mesh/D052689",
"about": {
"@type": "MedicalCondition",
"name": "Gammapapillomavirus",
"code": {
"@type": "MedicalCode",
"code": "D052689",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B04.613.204.655.400"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Virus des Papillomavirus humains",
"alternateName": "Human Papillomavirus Viruses",
"url": "https://questionsmedicales.fr/mesh/D000094302",
"about": {
"@type": "MedicalCondition",
"name": "Virus des Papillomavirus humains",
"code": {
"@type": "MedicalCode",
"code": "D000094302",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B04.613.204.655.450"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Papillomavirus humain de type 11",
"alternateName": "Human papillomavirus 11",
"url": "https://questionsmedicales.fr/mesh/D052140",
"about": {
"@type": "MedicalCondition",
"name": "Papillomavirus humain de type 11",
"code": {
"@type": "MedicalCode",
"code": "D052140",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B04.613.204.655.450.125"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Papillomavirus humain de type 16",
"alternateName": "Human papillomavirus 16",
"url": "https://questionsmedicales.fr/mesh/D052162",
"about": {
"@type": "MedicalCondition",
"name": "Papillomavirus humain de type 16",
"code": {
"@type": "MedicalCode",
"code": "D052162",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B04.613.204.655.450.250"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Papillomavirus humain de type 18",
"alternateName": "Human papillomavirus 18",
"url": "https://questionsmedicales.fr/mesh/D052161",
"about": {
"@type": "MedicalCondition",
"name": "Papillomavirus humain de type 18",
"code": {
"@type": "MedicalCode",
"code": "D052161",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B04.613.204.655.450.313"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Papillomavirus humain de type 31",
"alternateName": "Human papillomavirus 31",
"url": "https://questionsmedicales.fr/mesh/D058952",
"about": {
"@type": "MedicalCondition",
"name": "Papillomavirus humain de type 31",
"code": {
"@type": "MedicalCode",
"code": "D058952",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B04.613.204.655.450.375"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Papillomavirus humain de type 6",
"alternateName": "Human papillomavirus 6",
"url": "https://questionsmedicales.fr/mesh/D052163",
"about": {
"@type": "MedicalCondition",
"name": "Papillomavirus humain de type 6",
"code": {
"@type": "MedicalCode",
"code": "D052163",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B04.613.204.655.450.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Kappapapillomavirus",
"alternateName": "Kappapapillomavirus",
"url": "https://questionsmedicales.fr/mesh/D052690",
"about": {
"@type": "MedicalCondition",
"name": "Kappapapillomavirus",
"code": {
"@type": "MedicalCode",
"code": "D052690",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B04.613.204.655.500"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Papillomavirus du lapin à queue de coton",
"alternateName": "Cottontail rabbit papillomavirus",
"url": "https://questionsmedicales.fr/mesh/D012777",
"about": {
"@type": "MedicalCondition",
"name": "Papillomavirus du lapin à queue de coton",
"code": {
"@type": "MedicalCode",
"code": "D012777",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B04.613.204.655.500.150"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Lambdapapillomavirus",
"alternateName": "Lambdapapillomavirus",
"url": "https://questionsmedicales.fr/mesh/D052691",
"about": {
"@type": "MedicalCondition",
"name": "Lambdapapillomavirus",
"code": {
"@type": "MedicalCode",
"code": "D052691",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B04.613.204.655.520"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Mupapillomavirus",
"alternateName": "Mupapillomavirus",
"url": "https://questionsmedicales.fr/mesh/D052692",
"about": {
"@type": "MedicalCondition",
"name": "Mupapillomavirus",
"code": {
"@type": "MedicalCode",
"code": "D052692",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B04.613.204.655.540"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Xipapillomavirus",
"alternateName": "Xipapillomavirus",
"url": "https://questionsmedicales.fr/mesh/D052696",
"about": {
"@type": "MedicalCondition",
"name": "Xipapillomavirus",
"code": {
"@type": "MedicalCode",
"code": "D052696",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B04.613.204.655.950"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Papillomavirus bovin de type 4",
"alternateName": "Bovine papillomavirus 4",
"url": "https://questionsmedicales.fr/mesh/D052697",
"about": {
"@type": "MedicalCondition",
"name": "Papillomavirus bovin de type 4",
"code": {
"@type": "MedicalCode",
"code": "D052697",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B04.613.204.655.950.150"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Papillomaviridae",
"alternateName": "Papillomaviridae",
"code": {
"@type": "MedicalCode",
"code": "D027383",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "N P Kisseljova",
"url": "https://questionsmedicales.fr/author/N%20P%20Kisseljova",
"affiliation": {
"@type": "Organization",
"name": "FSBI «National Medical Research Center of Oncology named after N.N. Blokhin» of the Ministry of Health of Russia."
}
},
{
"@type": "Person",
"name": "M D Fedorova",
"url": "https://questionsmedicales.fr/author/M%20D%20Fedorova",
"affiliation": {
"@type": "Organization",
"name": "FSBI «National Medical Research Center of Oncology named after N.N. Blokhin» of the Ministry of Health of Russia."
}
},
{
"@type": "Person",
"name": "A E Zaikina",
"url": "https://questionsmedicales.fr/author/A%20E%20Zaikina",
"affiliation": {
"@type": "Organization",
"name": "FSBI «National Medical Research Center of Oncology named after N.N. Blokhin» of the Ministry of Health of Russia."
}
},
{
"@type": "Person",
"name": "N V Elkina",
"url": "https://questionsmedicales.fr/author/N%20V%20Elkina",
"affiliation": {
"@type": "Organization",
"name": "FSBI «National Medical Research Center of Oncology named after N.N. Blokhin» of the Ministry of Health of Russia."
}
},
{
"@type": "Person",
"name": "E E Goldobina",
"url": "https://questionsmedicales.fr/author/E%20E%20Goldobina",
"affiliation": {
"@type": "Organization",
"name": "FSBI «National Medical Research Center of Oncology named after N.N. Blokhin» of the Ministry of Health of Russia."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Visceral fat percentage for prediction of outcome in uterine cervical cancer.",
"datePublished": "2023-07-13",
"url": "https://questionsmedicales.fr/article/37453220",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ygyno.2023.06.581"
}
},
{
"@type": "ScholarlyArticle",
"name": "Impact of CD44 genetic variants on clinicopathological characteristics of uterine cervical cancer patients.",
"datePublished": "2024-05-27",
"url": "https://questionsmedicales.fr/article/38903932",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.7150/ijms.96414"
}
},
{
"@type": "ScholarlyArticle",
"name": "Radixin modulates the plasma membrane localization of CD47 in human uterine cervical adenocarcinoma cells.",
"datePublished": "2023-06-21",
"url": "https://questionsmedicales.fr/article/37364502",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jri.2023.103982"
}
},
{
"@type": "ScholarlyArticle",
"name": "Impact of MRI radiomic feature normalization for prognostic modelling in uterine endometrial and cervical cancers.",
"datePublished": "2024-07-22",
"url": "https://questionsmedicales.fr/article/39039099",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-024-66659-w"
}
},
{
"@type": "ScholarlyArticle",
"name": "Japan Society of Gynecologic Oncology 2022 guidelines for uterine cervical neoplasm treatment.",
"datePublished": "2023-11-27",
"url": "https://questionsmedicales.fr/article/38037547",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3802/jgo.2024.35.e15"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Virus",
"item": "https://questionsmedicales.fr/mesh/D014780"
},
{
"@type": "ListItem",
"position": 3,
"name": "Virus oncogènes",
"item": "https://questionsmedicales.fr/mesh/D009858"
},
{
"@type": "ListItem",
"position": 4,
"name": "Virus tumoraux à ADN",
"item": "https://questionsmedicales.fr/mesh/D004263"
},
{
"@type": "ListItem",
"position": 5,
"name": "Papillomaviridae",
"item": "https://questionsmedicales.fr/mesh/D027383"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Papillomaviridae - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Papillomaviridae",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-02-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Papillomaviridae",
"description": "Comment diagnostique-t-on une infection par le papillomavirus ?\nQuels tests sont utilisés pour détecter le HPV ?\nLes lésions cutanées sont-elles un signe de HPV ?\nLe col de l'utérus peut-il être examiné pour le HPV ?\nLes tests HPV sont-ils recommandés pour tous ?",
"url": "https://questionsmedicales.fr/mesh/D027383?mesh_terms=Uterine+Cervical+Neoplasms#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Papillomaviridae",
"description": "Quels sont les symptômes d'une infection par le HPV ?\nLes verrues génitales sont-elles douloureuses ?\nLe HPV peut-il causer des symptômes respiratoires ?\nComment reconnaître une lésion liée au HPV ?\nLe HPV peut-il être asymptomatique ?",
"url": "https://questionsmedicales.fr/mesh/D027383?mesh_terms=Uterine+Cervical+Neoplasms#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Papillomaviridae",
"description": "Comment prévenir une infection par le HPV ?\nÀ quel âge doit-on se faire vacciner contre le HPV ?\nLe dépistage régulier est-il important ?\nLes partenaires sexuels doivent-ils être vaccinés ?\nLes habitudes de vie influencent-elles le risque de HPV ?",
"url": "https://questionsmedicales.fr/mesh/D027383?mesh_terms=Uterine+Cervical+Neoplasms#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Papillomaviridae",
"description": "Quels traitements existent pour les verrues causées par le HPV ?\nLe HPV peut-il être guéri ?\nLes vaccins protègent-ils contre le HPV ?\nComment traite-t-on le cancer lié au HPV ?\nLes traitements sont-ils efficaces contre tous les types de HPV ?",
"url": "https://questionsmedicales.fr/mesh/D027383?mesh_terms=Uterine+Cervical+Neoplasms#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Papillomaviridae",
"description": "Quelles sont les complications possibles du HPV ?\nLe HPV peut-il causer des cancers autres que celui du col ?\nLes complications sont-elles fréquentes ?\nComment les complications du HPV sont-elles traitées ?\nLe suivi médical est-il nécessaire après un diagnostic de HPV ?",
"url": "https://questionsmedicales.fr/mesh/D027383?mesh_terms=Uterine+Cervical+Neoplasms#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Papillomaviridae",
"description": "Quels sont les principaux facteurs de risque du HPV ?\nLe nombre de partenaires sexuels influence-t-il le risque ?\nLes personnes immunodéprimées sont-elles plus à risque ?\nL'âge joue-t-il un rôle dans le risque de HPV ?\nLe tabagisme augmente-t-il le risque de cancer lié au HPV ?",
"url": "https://questionsmedicales.fr/mesh/D027383?mesh_terms=Uterine+Cervical+Neoplasms#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on une infection par le papillomavirus ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic se fait par des tests de dépistage, comme le frottis cervical et les tests HPV."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour détecter le HPV ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests PCR et les tests de hybridation sont couramment utilisés pour détecter le HPV."
}
},
{
"@type": "Question",
"name": "Les lésions cutanées sont-elles un signe de HPV ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les verrues et autres lésions cutanées peuvent indiquer une infection par le HPV."
}
},
{
"@type": "Question",
"name": "Le col de l'utérus peut-il être examiné pour le HPV ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un examen pelvien et un frottis peuvent détecter des anomalies liées au HPV."
}
},
{
"@type": "Question",
"name": "Les tests HPV sont-ils recommandés pour tous ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils sont recommandés pour les femmes à partir de 30 ans, selon les directives de santé."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une infection par le HPV ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Souvent asymptomatique, mais peut causer des verrues génitales ou des lésions cutanées."
}
},
{
"@type": "Question",
"name": "Les verrues génitales sont-elles douloureuses ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent être gênantes ou douloureuses, mais pas toujours."
}
},
{
"@type": "Question",
"name": "Le HPV peut-il causer des symptômes respiratoires ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Rarement, mais certains types peuvent provoquer des papillomes dans la gorge."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une lésion liée au HPV ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les lésions peuvent apparaître comme des excroissances ou des changements de couleur de la peau."
}
},
{
"@type": "Question",
"name": "Le HPV peut-il être asymptomatique ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, de nombreuses personnes infectées ne présentent aucun symptôme visible."
}
},
{
"@type": "Question",
"name": "Comment prévenir une infection par le HPV ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'utilisation de préservatifs et la vaccination sont des méthodes efficaces de prévention."
}
},
{
"@type": "Question",
"name": "À quel âge doit-on se faire vacciner contre le HPV ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le vaccin est recommandé entre 11 et 12 ans, mais peut être administré jusqu'à 26 ans."
}
},
{
"@type": "Question",
"name": "Le dépistage régulier est-il important ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le dépistage régulier aide à détecter les anomalies précoces et à prévenir le cancer."
}
},
{
"@type": "Question",
"name": "Les partenaires sexuels doivent-ils être vaccinés ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la vaccination des partenaires peut réduire le risque de transmission du HPV."
}
},
{
"@type": "Question",
"name": "Les habitudes de vie influencent-elles le risque de HPV ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes comme le tabagisme et une vie sexuelle à risque augmentent le risque."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour les verrues causées par le HPV ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la cryothérapie, les acides, et les traitements topiques."
}
},
{
"@type": "Question",
"name": "Le HPV peut-il être guéri ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de traitement antiviral spécifique, mais les symptômes peuvent être gérés."
}
},
{
"@type": "Question",
"name": "Les vaccins protègent-ils contre le HPV ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les vaccins comme Gardasil protègent contre certains types de HPV à haut risque."
}
},
{
"@type": "Question",
"name": "Comment traite-t-on le cancer lié au HPV ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement peut inclure chirurgie, radiothérapie et chimiothérapie selon le stade."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces contre tous les types de HPV ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, certains traitements ciblent spécifiquement les types de HPV responsables des verrues."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles du HPV ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent le cancer du col de l'utérus, des verrues génitales et des papillomes."
}
},
{
"@type": "Question",
"name": "Le HPV peut-il causer des cancers autres que celui du col ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il est lié à d'autres cancers, comme ceux de la gorge, de l'anus et du pénis."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "La plupart des infections par le HPV sont bénignes, mais certaines peuvent évoluer en cancer."
}
},
{
"@type": "Question",
"name": "Comment les complications du HPV sont-elles traitées ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement dépend de la complication, incluant chirurgie, radiothérapie ou surveillance."
}
},
{
"@type": "Question",
"name": "Le suivi médical est-il nécessaire après un diagnostic de HPV ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi régulier est essentiel pour surveiller les anomalies et prévenir le cancer."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque du HPV ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent une vie sexuelle active, le tabagisme et un système immunitaire affaibli."
}
},
{
"@type": "Question",
"name": "Le nombre de partenaires sexuels influence-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un nombre élevé de partenaires sexuels augmente le risque d'infection par le HPV."
}
},
{
"@type": "Question",
"name": "Les personnes immunodéprimées sont-elles plus à risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles sont plus susceptibles de développer des infections persistantes et des complications."
}
},
{
"@type": "Question",
"name": "L'âge joue-t-il un rôle dans le risque de HPV ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les jeunes adultes sont plus à risque, surtout ceux qui commencent leur vie sexuelle tôt."
}
},
{
"@type": "Question",
"name": "Le tabagisme augmente-t-il le risque de cancer lié au HPV ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est un facteur de risque connu pour le développement de cancers liés au HPV."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 08/01/2026
Contenu vérifié selon les dernières recommandations médicales
1 publication dans cette catégorie
Affiliations :
FSBI «National Medical Research Center of Oncology named after N.N. Blokhin» of the Ministry of Health of Russia.
Publications dans "Papillomaviridae" :
1 publication dans cette catégorie
Affiliations :
FSBI «National Medical Research Center of Oncology named after N.N. Blokhin» of the Ministry of Health of Russia.
Publications dans "Papillomaviridae" :
1 publication dans cette catégorie
Affiliations :
FSBI «National Medical Research Center of Oncology named after N.N. Blokhin» of the Ministry of Health of Russia.
Publications dans "Papillomaviridae" :
1 publication dans cette catégorie
Affiliations :
FSBI «National Medical Research Center of Oncology named after N.N. Blokhin» of the Ministry of Health of Russia.
Publications dans "Papillomaviridae" :
1 publication dans cette catégorie
Affiliations :
FSBI «National Medical Research Center of Oncology named after N.N. Blokhin» of the Ministry of Health of Russia.
Publications dans "Papillomaviridae" :
1 publication dans cette catégorie
Affiliations :
FSBI «National Medical Research Center of Oncology named after N.N. Blokhin» of the Ministry of Health of Russia.
Publications dans "Papillomaviridae" :
1 publication dans cette catégorie
Affiliations :
FSBI «National Medical Research Center of Oncology named after N.N. Blokhin» of the Ministry of Health of Russia.
Publications dans "Papillomaviridae" :
1 publication dans cette catégorie
Affiliations :
FSBI «National Medical Research Center of Oncology named after N.N. Blokhin» of the Ministry of Health of Russia.
Publications dans "Papillomaviridae" :
1 publication dans cette catégorie
Affiliations :
FSBI «National Medical Research Center of Oncology named after N.N. Blokhin» of the Ministry of Health of Russia.
Publications dans "Papillomaviridae" :
1 publication dans cette catégorie
Affiliations :
FSBI «Central Research Institute for Epidemiology» of the Surveillance of Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor).
Publications dans "Papillomaviridae" :
1 publication dans cette catégorie
Affiliations :
FSBI «Central Research Institute for Epidemiology» of the Surveillance of Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor).
Publications dans "Papillomaviridae" :
1 publication dans cette catégorie
Affiliations :
FSBI «Central Research Institute for Epidemiology» of the Surveillance of Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor); FSAEI HE «People's Friendship University of Russia».
Publications dans "Papillomaviridae" :
1 publication dans cette catégorie
Affiliations :
FSBI «Central Research Institute for Epidemiology» of the Surveillance of Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor).
Publications dans "Papillomaviridae" :
1 publication dans cette catégorie
Affiliations :
FSBI «Central Research Institute for Epidemiology» of the Surveillance of Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor).
Publications dans "Papillomaviridae" :
The prognostic role of adiposity in uterine cervical cancer (CC) is largely unknown. Abdominal fat distribution may better reflect obesity than body mass index. This study aims to describe computed to...
The study included 316 CC patients diagnosed during 2004-2017 who had pre-treatment abdominal CT. CT-based 3D segmentation of total-, subcutaneous- and visceral abdominal fat volumes (TAV, SAV and VAV...
High TAV, VAV and VAV% and low LD were associated with higher age (≥44 yrs.; p ≤ 0.017) and high International Federation of Gynecology and Obstetrics (FIGO) (2018) stage (p ≤ 0.01). High VAV% was the...
High VAV% is associated with high-risk clinical features and predicts reduced DSS in CC patients. Furthermore, patients with high VAV% had upregulated inflammatory tumor signaling, suggesting that the...
CD44 genetic variants have been found to be related to various cancers. However, to date, no study has demonstrated the involvement of CD44 polymorphisms in uterine cervical cancer in Taiwanese women....
Despite the dramatic success of immune checkpoint blockers in treating numerous cancer cell types, current therapeutic modalities provide clinical benefits to a subset of patients with cervical cancer...
Widespread clinical use of MRI radiomic tumor profiling for prognostication and treatment planning in cancers faces major obstacles due to limitations in standardization of radiomic features. The purp...
The Japan Society of Gynecologic Oncology (JSGO) Guidelines 2022 for the Treatment of Uterine Cervical Cancer are revised from the 2017 guideline. This guideline aimed to provide standard care for cer...
Radiotherapy is one of the main treatments for cervical cancer. Long-term complications of radiation exposure include the emergence of secondary tumors. This is a retrospective study based on an Ameri...
The study included patients with a definitive pathological diagnosis of cervical cancer who were diagnosed with a uterine malignant tumor ≥ 1 year later. Patients in whom cervical cancer was not the f...
We screened 142 patients with a secondary uterine malignancy after cervical cancer treatment, 115 patients with a secondary uterine malignancy after radiotherapy, and 27 patients with a secondary uter...
The results suggest that the treatment modality in patients with secondary uterine malignancy after radiotherapy for cervical cancer has a significant impact on survival. The survival outcomes of pati...
To discuss the dosimetric advantages and reliability of the accurate delivery of online adaptive radiotherapy(online ART) for uterine cervical cancer(UCC)....
Six UCC patients were enrolled in this study. 95% of the planning target volume (PTV) reached 100% of the prescription dose (50.4 Gy/28fractions/6weeks) was required. The patients were scanned with uR...
The inter-fractional volumes of the bladder and rectum changed greatly among the treatments. These changes influenced the primary gross tumor volume (GTVp) and the position deviation of GTVp and PTV a...
Online ART in external radiotherapy of UCC significantly improved the dose distribution and can become an ideal technology to achieve individualized precise radiotherapy....
Uterine cervical cancer (UCC) is the fourth most common cancer in women, responsible for more than 300 000 deaths worldwide. Its early detection, by cervical cytology, and prevention, by vaccinating a...
We analyzed 628 metabolites in plasma samples obtained from 45 patients with UCC using ultra-high-performance liquid chromatography with tandem mass spectrometry....
The levels of 47 metabolites were significantly increased and those of 75 metabolites were significantly decreased in patients with UCC relative to healthy controls. Increased levels of arginine and c...
Our findings suggest that the metabolite profile of patients with UCC may be an important indicator for distinguishing these patients from healthy cohorts, and may also be useful for predicting sensit...
Cervical cancer (CC) is a common gynecologic malignancy, accounting for a significant proportion of women death worldwide. Human papillomavirus (HPV) infection is one of the major etiological causes l...
We have been encouraging practicing gynecologists to adopt molecular diagnostics tests, PCR, and cancer biomarkers, as alternatives enabled by these platforms, to traditional Papanicolaou and colposco...